Morgan Lewis

Related Publications

07/25/12 FDA User Fee Act Full of Surprises for Pharma and Biotech
FDA user fee reauthorization law expands fees to include generic and biosimilar applications, and includes a new emphasis on drug supply chain safety and incentives for development of new therapies.
06/29/12 What Is the Device Industry Getting for Its Money?
FDA user fee reauthorization legislation seeks to ease premarket regulatory burdens, but increases postmarket scrutiny.
02/09/12 FDA Issues Three Draft Guidances for Biosimilars
Initial guidance provides insights on regulatory pathway for biosimilars, but does not address many critical issues.
View all publications

Related News

04/11/13 Morgan Lewis Advises MEI Pharma on $15.2 Million Registered Offering of Common Stock
Morgan Lewis served as legal adviser to MEI Pharma, Inc. on registered offering of common stock.
07/13/11 Morgan Lewis Team Advises Kinetic Concepts on Company’s $6.3 Billion Acquisition by Apax
Morgan Lewis advised Kinetic Concepts, Inc. (KCI), on a definitive merger agreement under which a consortium comprised of private equity funds will acquire KCI in a $6.3 billion transaction.
01/20/11 Morgan Lewis Advises Perrigo on $540 Million Acquisition of Paddock Assets
Morgan Lewis advised Perrigo Company, a global healthcare products supplier, on its acquisition of nearly all of the assets of Paddock Laboratories, Inc. for $540 million in cash.
View all news
Photo of  Phoebe Mounts

practice accolades

FDA & Healthcare

Ranked the second-largest U.S. healthcare law firm by Modern Healthcare (2012)

Recognized as a top 10 law firm within the Life Sciences Regulatory Super League by The Practical Law Company (PLC) (2012)

Listed as Recommended in PLC's Life Sciences Multi-Jurisdictional Guide (2012)

bar admissions

  • District of Columbia
  • Maryland
print profile

Phoebe Mounts
Partner


Email: pmounts@morganlewis.com
Washington, D.C.
1111 Pennsylvania Ave., NW
Washington, DC 20004-2541
Phone: 202.739.5898
Fax: 202.739.3001

Phoebe Mounts is a partner in Morgan Lewis's FDA Practice. Her practice is focused on FDA-related regulatory matters, particularly in the area of product development for drugs, biologics, medical devices, and human cell and tissue-based products.

Prior to joining Morgan Lewis, Dr. Mounts was on the faculty of The Johns Hopkins University School of Public Health for 16 years, where she was elected to the Delta Omega Public Health Honorary. She has published more than 45 articles in the areas of molecular biology and infectious diseases and has conducted research on the papillomavirus etiology of tumors of the respiratory and genital tracts. Her scientific background enables her to assist clients with emerging technologies and on issues involving preclinical studies to support product development and presentation of technical manufacturing information. Dr. Mounts prepares submissions to the FDA, including Investigational New Drug (IND), Investigational Device Exmption (IDE) and 510(k) applications, meeting requests, and background packages, and she attends meetings at the FDA with clients to facilitate product development. In addition to preparing clinical trial agreements, consent forms, and assisting in interactions with Institutional Review Boards, Dr. Mounts has conducted audits of clinical trial sites in preparation for FDA review of pivotal clinical trials and provides Good Clinical Practice training. She assists clients with privacy issues for clinical trial data, and has guided implementation of the safe harbor certification program. Dr. Mounts also has prepared applications for orphan drug designation, jurisdictional assignment within the FDA, negotiated Special Protocol Assessments, and assisted clients in appealing decisions by the review division. She has secured reclassification of a medical device, and in 2005, she received an award from the FDA "For outstanding teamwork and leveraging of public and private resources to support the timely down-classification of hepatitis A serological assays." She also is an active participant in the Food and Drug Law Institute/FDA In-House Training Program.

Dr. Mounts is admitted to practice in the District of Columbia and Maryland.

education

  • Georgetown University Law Center, 1999, J.D.
  • Johns Hopkins University, 1980, P.D.F.
  • University of Edinburgh, Scotland, 1977, Ph.D.
  • University of Pittsburgh, 1973, M.S.
  • University of Pittsburgh, 1971, B.S.